Abstract 461P
Background
Meta-analyses and cohort studies have shown blood trace mineral concentration may be associated with incidence risk of lung cancer. However, there is no comprehensive study to investigate causal relationship between blood trace mineral and lung cancer. The purpose of this study is to inspect the causal effect of blood trace mineral concentration on lung cancer with Mendelian randomization (MR) method.
Methods
With a two‐sample MR approach, we analyzed the summary data of zinc, selenium, copper from the Queensland Institute of Medical Research(QIMR, 2603 individuals) and The Avon Longitudinal Study of Parents and Children (ALSPAC, 10115 individuals), data of calcium from discovery cohorts(39400 individuals) and replication cohorts(21875 individuals), data of iron from Genetics of Iron Status Consortium(23986 individuals), data of lung cancer patients from Consortium and International Lung Cancer Consortium (ILCCO, 11 348 lung cancer cases and 15 861 controls) to assess the possible causal relationship of blood trace mineral concentration on the risk of lung cancer.
Results
Our results indicated that genetically predicted higher blood copper level has a positive association with lung cancer, each per-unit increase in copper is associated with a 14% increase in the risk of lung cancer (odds ratio [OR]: 1.14, 95% CI = 1.01‐1.29; P = 0.04). Additionally, blood calcium, zinc, selenium, iron were not causal factors for lung cancer.
Conclusions
Genetically higher blood copper is positively associated with risk of lung cancer, and more work is needed to examine the potential mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503); Science and Technology Program of Guangdong (Grant No. 2017B020227001, 2016A020215084); Science and Technology Program of Guangzhou (Grant No. 201607020031, 201400000001-2); Chinese National Natural Science Foundation project (Grant No. 81772476, 81572659,81602011); Pearl River Nova Program of Guangzhou (Grant No. 201610010048); National Natural Science Funds for Young Scholars of China (Grant No. 81502355).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract